Summary: New research shows that psychedelic compounds such as psilocybin do more than change neuronal activity — they reconfigure communication between the brain and the immune system. Scientists have traced a pathway in which chronic stress disrupts signaling in the amygdala, provoking an immune response that amplifies fear and anxiety. Psychedelics reverse this cascade, calming immune cells and reducing fear-related behavior, suggesting a new therapeutic route for psychiatric and inflammatory conditions.
These findings point to a broader view of mental health treatment: effective therapies may need to target neuroimmune circuits as well as neural circuits. By acting on both sides of the brain-immune conversation, psychedelics could offer explanations for benefits observed across depression, addiction, and inflammatory disorders.
Key Facts:
- Neuroimmune rewiring: Psychedelics can reset disrupted communication between the brain and the immune system caused by chronic stress.
- Therapeutic potential: Dual neural and immune actions may underlie psychedelic benefits in psychiatric and inflammatory diseases.
- Paradigm shift: The work supports expanding mental health strategies to address both neural circuitry and immune signaling.
Source: Genomic Press
Overview of the study and implications
In a detailed interview published today by Genomic Press, Dr. Michael Wheeler, an assistant professor at Harvard Medical School and an investigator at Brigham and Women’s Hospital, presents evidence that psychedelics reshape brain-immune interactions in ways that reduce fear and inflammation. His lab’s work, recently reported in Nature (April 23, 2025; https://doi.org/10.1038/s41586-025-08880-9), shows that these compounds act beyond neurons to alter immune responses linked to stress and anxiety.
Dr. Wheeler explains that astrocytes in the amygdala use the EGFR receptor to limit fear responses triggered by stress. Chronic stress can impair this signaling, initiating a cascade that recruits brain-resident and peripheral immune cells, particularly in the meninges, which escalates fear-related behaviors. The team found that psychedelic compounds can reverse this cascade, normalizing immune activation and reducing anxiety-like responses in experimental models.
This research reframes how we think about psychopharmacology: instead of acting only on synapses and neurotransmitters, effective treatments may need to rebalance neuroimmune dialogs. That perspective could explain why psychedelics have shown promise across a diverse range of conditions, from treatment-resistant depression and substance use disorders to disorders with inflammatory components.
From public defender to neuroimmunologist
Dr. Wheeler’s path to neuroimmunology began unexpectedly in the public defender’s office in Baltimore City. Confronted with clients whose behavior reflected deep environmental and traumatic influences, he became determined to understand how stress and trauma alter the brain’s biology. That curiosity led him to a bold decision during his postdoctoral training: he joined an immunology lab despite having trained primarily in neuroscience.
That interdisciplinary leap proved critical. Combining tools and perspectives from both fields enabled his team to discover previously hidden communication channels between the brain and immune system — mechanisms that may help explain variable outcomes with conventional psychiatric treatments.
Mapping the brain-immune interface
Dr. Wheeler’s lab uses genomic screening, single-cell analysis, and behavioral experiments to build a detailed “wiring diagram” of brain-immune communication. Their Nature paper documents how chronic stress alters amygdala signaling, producing an inflammatory response in the meninges and promoting fear behaviors. Importantly, psychedelic treatments were able to interrupt this signaling at several stages, reducing immune cell accumulation and the associated behavioral consequences.
These results raise practical questions for clinicians and researchers: should treatments for psychiatric disorders include agents that modulate the immune system or neuroimmune signaling? Could such combined approaches improve outcomes for patients who do not respond to traditional therapies that focus solely on neurotransmitters?
Dr. Wheeler envisions a future where identifying and targeting brain-body communication loops becomes a core part of diagnosing and treating neuropsychiatric disorders. He argues that focusing exclusively on behavior and neural circuits risks overlooking key biological contributors that determine disease risk and treatment response.
Collaboration and team science
Dr. Wheeler credits his accomplishments to collaborative, cross-disciplinary science rather than individual effort. He emphasizes recruiting researchers from diverse scientific and personal backgrounds to foster creative exchange and accelerate discovery. This team-based approach, he says, echoes lessons from his undergraduate years at Johns Hopkins: great science requires a great team.
About this psychopharmacology and immune system research news
Author: Ma-Li Wong
Source: Genomic Press
Contact: Ma-Li Wong – Genomic Press
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Psychedelics and neuroimmune circuits—what a strange trip, indeed” by Michael Wheeler et al. Psychedelics